Stoke Therapeutics stock barely flinched after its Q3 2026 report, edging down 0.2% to US$26.29. On the surface, that muted move suggests a non event. The actual print tells a sharper story. Management reported Q3 revenue of US$11.3m alongside a net loss of US$73.6m as the company funds late stage work on zorevunersen and earlier stage spend on STK 002.
Short term traders are staring at red ink. Long term holders are weighing that widening loss profile against a multi year development plan and an early read on valuation signals.
Like the Stoke Therapeutics story but uneasy about a widening loss profile and heavy R&D spend? You can filter for biotechs with stronger cash generation and cleaner balance sheets using the list of solid balance sheet and fundamentals stocks (25 results).
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): US$11.26m vs. US$10.63m (change of about 5.9% higher)
- Net Loss (Q3 2026 vs. Q3 2025): US$73.64m loss vs. US$38.35m loss (loss widened by about 92.0%)
- Basic EPS (Q3 2026 vs. Q3 2025): US$1.08 loss per share vs. US$0.65 loss per share (loss per share widened by about 64.6%)
- Cash Runway (as of Q3 2026): US$358.8m in cash, equivalents and marketable securities, with management indicating funding into early 2028 when including expected partner reimbursements and potential milestone payments
The FDA just backed Stoke’s custom Vineland-3 endpoint for Dravet. Ask Charlie what Stoke’s FDA call changed for the 2027 filing.
Evaluating Stoke’s Dravet Franchise Ambition
For Stoke Therapeutics, the bullish view hangs on turning today’s R&D engine into tomorrow’s Dravet franchise.
"Bullish analysts expect Stoke Therapeutics to turn zorevunersen’s multi year seizure reduction and Vineland-3 gains, plus a lean rare disease commercial model, into a durable Dravet syndrome franchise and proof of concept for a broader haploinsufficiency platform."
Q3 progress lines up with that ambition on execution milestones rather than outcomes. EMPEROR is fully enrolled at 162 patients with no discontinuations and powered for both seizure and Vineland multicomponent endpoints. The FDA has agreed to the Vineland MC4 framework and Stoke is already building out medical affairs and payer outreach. The science still needs to read out, but the clinical and commercial scaffolding is now largely in place.
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.
Stoke Therapeutics Bear Case: Cash Burn Without New Proof
Bears argue Stoke Therapeutics will keep burning cash long before real-world demand is clear.
"Although Stoke reports US$411 million in cash and expects funding through a potential U.S. launch window, continued investment in EMPEROR, open label studies and a commercial build out, even if lean, could keep expenses elevated and delay the path to positive earnings until after the market response to launch is clearer."
The latest quarter supports that concern. Revenue sits at US$11.3m while the net loss widened to US$73.6m, with US$11m of that non cash. Cash of US$358.8m and runway into early 2028 match guidance, yet no new de risking efficacy data arrived to offset the heavier spend.
Hunt Quiet Disconnects In Plain Sight
Stoke Therapeutics just reminded investors that heavy R&D spend can leave the share price treading water. The real opportunity is finding stocks that could be undervalued before the market corrects them.
- Company 1 - 38% below our estimate - use strong power systems demand and capacity expansion to pursue extended data center engine contracts.
- Company 2 - 34% below our estimate - turn sizable optical and solar order books plus customer prepayments into long duration supply agreements.
- Company 3 - 22% below our estimate - ride a growing data center construction backlog across communications and infrastructure segments while managing higher working capital needs.
Three companies from the same screener. Open every one of the 29 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com